Organization Profile

You just read:

Aeterna Zentaris: Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin (AEZS-108) in Prostate Cancer Reported at ASCO

News provided by

Aeterna Zentaris Inc.

Jun 03, 2013, 09:05 ET